CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 87.41% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Scan to Download iOS&Android APP

Trade Jaguar Health, Inc. - JAGX CFD

-
0%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread -
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.0308 %
Charges from borrowed part ($-1.23)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.0308%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.0308 %
Charges from borrowed part ($-1.23)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.0137%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 20%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* N/A
Open* N/A
1-Year Change* N/A
Day's Range* N/A
52 wk Range 0.1151-1.885
Average Volume (10 days) 2.78656
Average Volume (3 months) 67.5982
Market Cap 17.6463
P/E Ratio N/A
Shares Outstanding 145343000
Revenue 10.776
EPS -0.78583
Dividend (Yield %) N/A
Beta 1.67693
Next Earnings Date Mar 9, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low

Jaguar Health, Inc. Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total revenue 0.14152 4.36119 4.41615 5.77526 9.385 4.335
Revenue 0.14152 4.36119 4.41615 5.77526 9.385 4.335
Cost of Revenue, Total 0.05197 0.88041 2.76575 3.81581 3.28 2.333
Gross Profit 0.08955 3.48078 1.6504 1.95945 6.105 2.002
Total Operating Expense 13.8355 39.0853 34.5802 39.6643 37.896 45.796
Selling/General/Admin. Expenses, Total 6.46868 14.3314 22.1088 20.4389 20.996 25.997
Research & Development 7.20686 4.26946 5.15475 5.81982 6.413 15.079
Unusual Expense (Income) 0.108 19.604 4.55093 9.58971 7.207 2.387
Operating Income -13.694 -34.7241 -30.1641 -33.889 -28.511 -41.461
Interest Income (Expense), Net Non-Operating -1.02875 -0.51429 -2.29767 -4.72125 -5.488 -10.374
Other, Net -0.01105 0.08855 0.31569 0.08083 0.19 -0.765
Net Income Before Taxes -14.7338 -35.1499 -32.1461 -38.5294 -33.809 -52.6
Net Income After Taxes -14.7338 -21.9686 -32.1461 -38.5394 -33.809 -52.6
Net Income Before Extra. Items -14.7338 -21.9686 -32.1461 -38.5394 -33.809 -52.595
Net Income -14.7338 -21.9686 -32.1461 -38.5394 -33.809 -52.595
Total Adjustments to Net Income 0 -6.18681 -4.839 0
Income Available to Common Excl. Extra. Items -14.7338 -21.9686 -32.1461 -44.7262 -38.648 -52.595
Income Available to Common Incl. Extra. Items -14.7338 -21.9686 -32.1461 -44.7262 -38.648 -52.595
Diluted Net Income -14.7338 -21.9686 -32.1461 -44.7262 -38.648 -52.595
Diluted Weighted Average Shares 0.00348 0.96523 0.06991 1.6551 12.8807 44.7116
Diluted EPS Excluding Extraordinary Items -4236.8 -22.7599 -459.827 -27.0234 -3.00045 -1.17632
Dividends per Share - Common Stock Primary Issue 0
Diluted Normalized EPS -4205.74 -9.55829 -394.729 -23.2572 -2.44093 -1.12293
Total Extraordinary Items 0
Minority Interest 0.005
Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022
Total revenue 1.241 0.385 0.63 2.08 2.625
Revenue 1.241 0.385 0.63 2.08 2.625
Cost of Revenue, Total 0.583 0.664 0.617 0.469 0.455
Gross Profit 0.658 -0.279 0.013 1.611 2.17
Total Operating Expense 10.76 11.965 10.159 12.902 17.194
Selling/General/Admin. Expenses, Total 5.548 7.259 6.23 6.951 8.979
Research & Development 2.414 3.87 3.312 5.482 4.945
Unusual Expense (Income) 2.215 0.172 0 0 2.815
Operating Income -9.519 -11.58 -9.529 -10.822 -14.569
Interest Income (Expense), Net Non-Operating -2.5 -2.484 -2.643 -2.747 -4.427
Other, Net 0.01 -0.017 -0.02 -0.749 0.832
Net Income Before Taxes -12.009 -14.081 -12.192 -14.318 -18.164
Net Income After Taxes -12.009 -14.081 -12.192 -14.318 -18.164
Net Income Before Extra. Items -12.009 -14.081 -12.192 -14.313 -17.986
Net Income -12.009 -14.081 -12.192 -14.313 -17.986
Total Adjustments to Net Income 0 0 0 0
Income Available to Common Excl. Extra. Items -12.009 -14.081 -12.192 -14.313 -17.986
Income Available to Common Incl. Extra. Items -12.009 -14.081 -12.192 -14.313 -17.986
Diluted Net Income -12.009 -14.081 -12.192 -14.313 -17.986
Diluted Weighted Average Shares 41.805 44.8117 45.8403 46.3427 44.7116
Diluted EPS Excluding Extraordinary Items -0.28726 -0.31423 -0.26597 -0.30885 -0.40227
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.23428 -0.31039 -0.26597 -0.30885 -0.33931
Minority Interest 0.005 0.178
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total Current Assets 2.55504 3.7991 8.14994 9.52235 17.792 28.434
Cash and Short Term Investments 0.95098 0.5207 2.56819 3.49543 8.09 17.051
Cash & Equivalents 0.95098 0.5207
Total Receivables, Net 0.00496 0.46904 1.0018 1.69458 4.56 2.144
Accounts Receivable - Trade, Net 0.00496 0.46766 0.99568 1.69171 4.532 1.709
Total Inventory 0.41275 2.07282 3.34218 2.12869 2.782 4.9
Prepaid Expenses 0.30269 0.49737 1.23777 1.26274 2.36 4.339
Other Current Assets, Total 0.88365 0.23917 0 0.94091 0
Total Assets 3.56315 43.6292 41.042 36.4104 42.843 53.265
Property/Plant/Equipment, Total - Net 0.88595 1.22207 0.76062 0.71021 0.677 1.734
Other Long Term Assets, Total 0.12216 0 0.42083 0.15397 0.037 0.446
Total Current Liabilities 4.19285 15.3858 26.6588 15.3924 13.22 15.471
Accounts Payable 0.517 7.35493 5.41426 5.35154 4.759 4.929
Accrued Expenses 0.58252 2.19955 4.93944 3.2589 4.493 7.357
Notes Payable/Short Term Debt 0 1.14115 4.84558 0 0 0
Current Port. of LT Debt/Capital Leases 2.06968 4.28146 11.2392 6.77846 3.789 3.184
Other Current Liabilities, Total 1.02366 0.40867 0.22038 0.00349 0.179 0.001
Total Liabilities 6.01733 26.3682 26.6588 15.8424 25.641 41.654
Total Long Term Debt 1.81753 10.9824 0 0.45 12.421 25.022
Long Term Debt 1.81753 10.9824 0 0.45 12.421 25.022
Other Liabilities, Total 0.00696 0 0.919
Total Equity -2.45419 17.261 14.3831 20.568 17.202 11.611
Redeemable Preferred Stock 0 0 9 11.6065 0 0
Common Stock 0.0014 0.01053 0.00649 0.00546 0.011 0.005
Additional Paid-In Capital 37.9805 79.6552 99.9274 142.046 184.09 231.1
Retained Earnings (Accumulated Deficit) -40.4361 -62.4047 -94.5508 -133.09 -166.899 -219.494
Total Liabilities & Shareholders’ Equity 3.56315 43.6292 41.042 36.4104 42.843 53.265
Total Common Shares Outstanding 0.00445 42.6378 40.4184 45.0589 40.1279 50.4733
Goodwill, Net 5.21082 0
Intangibles, Net 33.3972 31.7106 26.0239 24.337 22.651
Cash 2.56819 3.49543 8.09 17.051
Property/Plant/Equipment, Total - Gross 0.93428 0.942 2.032
Accumulated Depreciation, Total -0.22407 -0.265 -0.298
Total Preferred Shares Outstanding 5.53706 0 0
Minority Interest 0.242
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Total Current Assets 44.104 44.294 24.005 28.434 28.474
Cash and Short Term Investments 32.25 21.992 12.375 17.051 17.456
Cash 32.25 21.992 12.375 17.051 17.456
Total Receivables, Net 5.927 4.174 2.205 2.144 2.255
Accounts Receivable - Trade, Net 5.897 4.134 2.111 1.709 1.795
Total Inventory 2.821 3.402 4.513 4.9 4.879
Prepaid Expenses 3.106 4.806 4.912 4.339 3.884
Other Current Assets, Total 0 9.92
Total Assets 68.713 69.539 59.255 53.265 52.906
Property/Plant/Equipment, Total - Net 0.674 1.751 1.7 1.734 1.757
Property/Plant/Equipment, Total - Gross 0.948 2.033 1.99 2.032 2.18
Accumulated Depreciation, Total -0.274 -0.282 -0.29 -0.298 -0.423
Intangibles, Net 23.916 23.494 23.072 22.651 22.229
Other Long Term Assets, Total 0.019 0 10.478 0.446 0.446
Total Current Liabilities 12.592 12.652 11.951 15.471 19.093
Accounts Payable 4.74 4.918 3.786 4.929 3.708
Accrued Expenses 6.409 6.582 6.381 7.357 8.494
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 1.431 1.145 1.781 3.184 6.89
Other Current Liabilities, Total 0.012 0.007 0.003 0.001 0.001
Total Liabilities 36.822 37.754 37.703 41.654 44.861
Total Long Term Debt 24.23 24.195 24.926 25.022 24.783
Long Term Debt 24.23 24.195 24.926 25.022 24.783
Total Equity 31.891 31.785 21.552 11.611 8.045
Redeemable Preferred Stock 0 0 0 0 0
Common Stock 0.013 0.014 0.005 0.005 0.008
Additional Paid-In Capital 210.786 224.76 226.728 231.1 245.517
Retained Earnings (Accumulated Deficit) -178.908 -192.989 -205.181 -219.494 -237.48
Total Liabilities & Shareholders’ Equity 68.713 69.539 59.255 53.265 52.906
Total Common Shares Outstanding 44.7563 47.8944 48.2117 50.4733 79.1948
Total Preferred Shares Outstanding 0 0 0 0 0
Other Liabilities, Total 0.907 0.826 0.919 0.921
Minority Interest 0.242 0.064
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Net income/Starting Line -14.7338 -21.9686 -32.1461 -38.5394 -33.809 -52.6
Cash From Operating Activities -14.4137 -9.82494 -22.7308 -20.4568 -15.278 -34.97
Cash From Operating Activities 0.04749 0.58434 1.319 1.73708 1.727 1.719
Non-Cash Items 1.41841 20.6123 9.02132 17.0073 20.271 13.644
Cash Interest Paid 0.47867 0.23455 0.01934 0.142 0.757 0.028
Changes in Working Capital -1.14584 4.12831 -0.9251 -0.66177 -3.467 2.267
Cash From Investing Activities 2.3845 -1.55734 -0.00653 0 -0.007 -0.006
Capital Expenditures -0.10421 0 -0.00653 -0.007 -0.006
Other Investing Cash Flow Items, Total 2.48871 -1.55734 0 0
Cash From Financing Activities 5.28267 10.6799 24.5457 21.772 19.492 43.937
Financing Cash Flow Items -1.05538 0 -2.11755 -2.57481 -1.008 -0.731
Issuance (Retirement) of Stock, Net 7.67675 10.302 25.8797 24.4468 7.756 35.615
Issuance (Retirement) of Debt, Net -1.33871 0.37791 0.78349 -0.1 12.744 9.053
Net Change in Cash -6.74655 -0.70241 1.80832 1.31519 4.207 8.961
Deferred Taxes -13.1812 0
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Net income/Starting Line -12.009 -26.09 -38.282 -52.6 -18.164
Cash From Operating Activities -6.708 -16.615 -26.047 -34.97 -7.695
Cash From Operating Activities 0.431 0.861 1.29 1.719 0.426
Non-Cash Items 4.695 7.609 10.601 13.644 7.583
Cash Interest Paid 0.006 0.008 0.021 0.028 0.011
Changes in Working Capital 0.175 1.005 0.344 2.267 2.46
Cash From Investing Activities 0 -0.006 -10.484 -0.006
Capital Expenditures 0 -0.006 -0.006 -0.006
Cash From Financing Activities 30.868 40.443 40.816 43.937 8.15
Financing Cash Flow Items -0.095 -0.268 -0.623 -0.731 -0.335
Issuance (Retirement) of Stock, Net 21.86 31.608 32.386 35.615 9.11
Issuance (Retirement) of Debt, Net 9.103 9.103 9.053 9.053 -0.625
Net Change in Cash 24.16 23.822 4.285 8.961 0.405
Other Investing Cash Flow Items, Total -10.478
Foreign Exchange Effects -0.05

Why choose Capital.com? Our numbers speak for themselves.

Capital.com Group
475000+

Traders

71000+

Active clients monthly

$51000000+

Monthly investing volume

$30000000+

Withdrawn each month

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

Jaguar Health, Inc. Company profile

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. It operates through two reportable segments, Human Health and Animal Health. The company, through its subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest areas. It markets Mytesi, a crofelemer 125 mg delayed-release tablet for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. It develops Mytesi for multiple possible follow-on indications, including diarrhea related to targeted cancer therapy; orphan-drug indications for infants and children with congenital diarrheal disorders and short bowel syndrome; supportive care for inflammatory bowel disease; irritable bowel syndrome; and for idiopathic/functional diarrhea, as well as a second-generation proprietary anti-secretory agent is in development for cholera. The company also develops Crofelemer, a drug product candidate for chemotherapy-induced diarrhea in dogs. Jaguar Health, Inc. was incorporated in 2013 and is headquartered in San Francisco, California.
Industry: Bio Therapeutic Drugs

200 Pine Street Suite 400
SAN FRANCISCO
CALIFORNIA 94104
US

Income Statement

People also watch

Natural Gas

7.05 Price
-2.100% 1D Chg, %
Long position overnight fee -0.1770%
Short position overnight fee 0.1298%
Overnight fee time 22:00 (UTC)
Spread 0.005

Oil - Crude

74.19 Price
-3.160% 1D Chg, %
Long position overnight fee -0.0085%
Short position overnight fee -0.0063%
Overnight fee time 22:00 (UTC)
Spread 0.03

BTC/USD

16,273.25 Price
-2.050% 1D Chg, %
Long position overnight fee -0.0500%
Short position overnight fee 0.0140%
Overnight fee time 22:00 (UTC)
Spread 60.00

US100

11,698.50 Price
-0.500% 1D Chg, %
Long position overnight fee -0.0167%
Short position overnight fee 0.0060%
Overnight fee time 22:00 (UTC)
Spread 1.8

Still looking for a broker you can trust?

Join the 475.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading